News & Events

• October 28, 2020
  

  C-Path and EATRIS To Collaborate on RDCA-DAP

  C-Path has signed a Memorandum of Understanding with EATRIS, the European infrastructure for translational medicine, to accelerate drug development for rare diseases by increasing the efficiency of translation of potential therapeutics through preclinical and clinical development …

• October 27, 2020
  

  FDA Awards C-Path Grant to Use Real-World Data to Generate Real-World Evidence in Neonates

  Pilot project will include the development of a Real-World Data and Analytics Platform TUCSON, Ariz., October 27, 2020 — Arizona-based Critical Path Institute (C-Path) is pleased to announce it has been awarded a multi-year grant by the U.S. Food and Drug Administration (FDA) to advance standards and methodologies designed to generate real-world evidence (RWE) from...
• October 21, 2020
  

  Rare Disease Cures Accelerator-Data and Analytics Platform First Year Milestones Highlighted at Virtual Workshop

      C-Path, NORD, FDA and more come together to showcase the importance of data sharing in rare disease drug development   TUCSON, Ariz. and WASHINGTON, D.C. October 21, 2020 — The Critical Path Institute (C-Path) and the National Organization for Rare Disorders (NORD®) hosted the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP) 2020 Virtual Workshop on...
• September 21, 2020
  

  C-Path Awarded FDA Drug Development Tool Research Grant to Develop a Qualification Plan for the Symptoms of Major Depressive Disorder Momentary Assessment (SMDDMA)

  C-Path’s Patient-Reported Outcome (PRO) Consortium announced that it has been awarded a U.S. Food and Drug Administration (FDA) Drug Development Tool Research Grant in support of the qualification of the Symptoms of Major Depressive Disorder Momentary Assessment (SMDDMA) as a self-reported measure of symptom severity in individuals diagnosed with major depressive disorder (MDD). C-Path’s PRO...
• September 17, 2020
  

  C-Path Launches Consortium to Accelerate Medical Product Development in Sickle Cell Disease

  TUCSON, Ariz., Sept. 17, 2020 — The Critical Path Institute (C-Path) today announced the launch of the Critical Path for Sickle Cell Disease (CP-SCD) Consortium to support collaboration and regulatory endorsement of new medical product development tools for sickle cell disease. These tools will help to optimize and de-risk clinical trials to increase efficiency in developing and delivering safe, effective treatments for people living with sickle cell disease.